CD274 and colorectal carcinoma: Furthermore, exploratory biomarker analysis of PD-L1 expression (≥1% or <1%) showed no significant difference in ORR (28.6% vs 27.7%) and DCR ≥12 weeks (52.4% vs 74.5%) in the nivolumab arm for CRC patients, suggesting that PD-L1 is not a predictive biomarker in these patients (10).